[1]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101-104.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(01):101-104.[doi:10.3969/j.issn.1671-7414.2020.01.027]
点击复制

初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年01期
页码:
101-104
栏目:
论　　著
出版日期:
2020-02-29

文章信息/Info

Title:
Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed Multiple Myeloma Patients
文章编号:
1671-7414(2020)01-101-04
作者:
张 蓉1; 李国辉2; 刘小五1; 刘 赞1; 徐静1; 王丽萍1; 梁英民1
(1.西安高新医院血液科,西安 710065; 2.空军军医大学唐都医院血液科,西安 710038)
Author(s):
ZHANG Rong1;  LI Guo-hui2; LIU Xiao-wu1;  LIU Zan1;  XU Jing1;  WANG Li-ping1 LIANG Ying-min1
(1.Department of Blood,Xi'an High Tech Hospital, Xi'an 710065, China; 2. Department of Blood,Tangdu Hospital of Air Force Military Medical University,Xi'an 710038, China)
关键词:
多发性骨髓瘤;  淋巴细胞绝对计数;  单核细胞绝对计数;  总体生存;  无进展生存
分类号:
R733.3; R730.43
DOI:
10.3969/j.issn.1671-7414.2020.01.027
文献标志码:
A
摘要:
目的 探讨淋巴细胞绝对计数(absolute lymphocyte count,ALC)和单核细胞绝对计数(absolute monocyte count,AMC)比值(ALC/AMC)在预测初诊多发性骨髓瘤(multiple myeloma,MM)患者临床预后中的价值。方法 选取372例初发MM患者为研究对象,收集患者入院时的一般资料,比较患者五年总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS)率及分析其危险因素。结果 ALC/AMC的阈值为3.6,ALC/AMC≥3.6和ALC/AMC<3.6患者的年龄、β2微球蛋白、血红蛋白、髓外疾病、ISS分期、del(17p),t(4; 14)和二倍体差异均有统计学意义(t=3.247,6.097,8.236,χ2=9.147,10.618,5.913,5.239,6.190,均P<0.05)。ALC/AMC≥3.6和ALC/AMC<3.6患者五年OS和PFS率之间差异有统计学意义,且ALC/AMC≥3.6的患者高于ALC/AMC<3.6患者(P<0.001)。ALC/AMC<3.6是预测MM患者五年OS和PFS率降低的独立危险因素。结论 外周血ALC/AMC的降低能有效预测初发MM患者的总体生存率和无进展生存率。
Abstract:
Objective To investigate the value of absolute lymphocyte count(ALC)and absolute monocyte count(AMC)ratio(ALC/AMC)in patients with newly diagnosed multiple myeloma(MM). Methods A total of 372 patients with newly diagnosed MM were selected as research objects, and the general data of patients upon admission were collected to compare the five-year OS and PFS rates of patients and analyzed their risk factors.Results The threshold value of ALC/AMC was 3.6. There existed significant differences in age, beta 2 microglobulin, hemoglobin, extramedullary diseases, ISS stages, del(17p), t(4; 14)and diploid among ALC/AMC≥3.6 and ALC/AMC<3.6 patients(t=3.247,6.097,8.236,χ2=9.147,10.618,5.913,5.239,6.190,all P<0.05). There were statistically significant differences between ALC/AMC≥3.6 and ALC/AMC<3.6 overall survival(OS)and progress free survival(PFS)rates and ALC/AMC≥3.6 patients were higher than ALC/AMC<3.6(P<0.001). ALC/AMC<3.6 was an independent risk factor for predicting 5-year decrease in OS and PFS rates in MM patients. Conclusion The reduction of peripheral blood ALC to AMC ratio can effectively predict the OS and PFS rates of patients with newly diagnosed MM.

参考文献/References:

[1] 陈文明. 复发难治性多发性骨髓瘤治疗进展[J]. 中国实用内科杂志, 2016, 36(2):116-120. CHEN Wenming. Treatment of relapsed and refractory multiple myeloma[J]. Chinese Journal of Practical Internal Medicine, 2016, 36(2):116-120.
[2] HOYOS V, BORRELLO I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapies[J]. Blood, 2016, 128(13):1679-1687.
[3] 常子维, 朱华峰, 冯苗娟, 等. 160例多发性骨髓瘤患者免疫表型特征及其临床意义[J]. 现代生物医学进展, 2016, 16(26):5179-5183,5148. CHANG Ziwei, ZHU Huafeng, FENG Miaojuan, et al. Immunophenotype Characteristics in 160 cases of patients with multiple myeloma and their clinical significance[J]. Progress in Modern Biomedicine, 2016, 16(26):5179-5183,1548.
[4] RODRGUEZ-OTERO P, PAIVA B, ENGELHARDT M, et al. Is immunotherapy here to stay in multiple myeloma?[J]. Haematologica, 2017, 102(3):423-432.
[5] 许彭鹏, 钱樱, 陈秋生, 等. 外周血淋巴与单核细胞绝对计数比值在滤泡性淋巴瘤中的预后意义[J]. 中国癌症杂志, 2016, 26(10):861-865. XU Pengpeng, QIAN Ying, CHEN Qiusheng, et al. The prognostic significance of peripheral blood ALC/AMC in follicular lymphoma patients treated with R-CHOP-like chemotherapy[J]. China Oncology, 2016, 26(10):861-865.
[6] BENDER B S, NAGEL J E, ADLER W H, et al. ABSOLUTE peripheral blood lymphocyte count and subsequent mortality of elderly men. The baltimore longitudinal study of aging[J]. J Am Geriatr Soc, 1986, 34(9):649-654.
[7] SONG M K, CHUNG J S, JOO Y D, et al. Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients[J]. Acta Haematol, 2010, 124(1):34-39.
[8] JIMENEZ-ZEPEDA V H, REECE D E, TRUDEL S, et al. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant[J]. Leuk Lymphoma, 2015, 56(9):2668-2673.
[9] MASUCCI G V, CESANO A, HAWTIN R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation[J]. J Immunother Cancer, 2016, 4:76.
[10] 刘玉霞,胡国瑜,袁朝晖, 等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(2):58-61. LIU Yuxia, HU Guoyu, YUAN Chaohui, et al. Expression of CD269 and CD317 in mutiple myeloma and its clinical significance[J]. J Mod Lab Med, 2018,33(2):58-61.
[11] 盘国雄,谭才燕,何嘉颖, 等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(1):72-76. PAN Guoxiong, TAN Caiyan, HE Jiaying,et al. Serum LncRNA PCAT-1 expression level of patients with mutiple myeloma and clinical value[J]. J Mod Lab Med, 2018,33(1):72-76.
[12] 谭奎,沈婵娟,张玲, 等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(6):64-66. TAN Kui, SHEN Chanjuan, ZHANG Ling, et al. Differential expression of CD269 and CD317 genes in bone marrow of patients with mutiple myeloma[J]. J Mod Lab Med, 2017,32(6):64-66.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(01):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(01):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(01):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(01):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(01):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[9]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(01):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
[10]徐海燕,陆学东.多发性骨髓瘤早期实验诊断相关新兴生物标志物的最新研究进展[J].现代检验医学杂志,2021,36(05):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
　XU Hai-yan,LU Xue-dong.Recent Research Rrogress of Novel Biomarkers for Early ExperimentalDiagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(01):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]

备注/Memo

备注/Memo:
基金项目:陕西省卫生计生科研基金项目(2016D062)。 作者简介:张蓉(1968-),女,硕士,副主任医师,研究方向:白血病、淋巴瘤,E-mail:xizhangr@163.com。 通讯作者:梁英民(1957-),男,硕士,主任医师,研究方向:血液病临床科研与教学,E-mail:liangym@fmmu.edu.cn。 收稿日期:2019-08-14 修稿日期:2019-09-03
更新日期/Last Update: 2020-03-30